NCI To Use Thomson Reuters' Biomarker Database | GenomeWeb
NEW YORK (GenomeWeb News) - Thomson Reuters said today that the National Cancer Institute will use the company’s BiomarkerCenter database to support its research on potential cancer therapeutics.
 
Thomson Reuters said that NCI’s Developmental Therapeutics program and its associated Biomarker Program will use BiomarkerCenter, a database of information on biomarkers that alerts uses to status changes of biomarkers of interest. The company launched the database in June.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.